The global pemphigus vulgaris market is witnessing significant growth due to the increasing prevalence of autoimmune skin disorders, rising awareness regarding rare diseases, and continuous advancements in targeted biologic therapies. The global pemphigus vulgaris market size was valued at USD 550.74 million in 2025 and is projected to grow from USD 595.9 million in 2026 to USD 1,119.42 million by 2034, registering a CAGR of 8.2% during the forecast period (2026–2034).

The market is expanding as healthcare providers increasingly focus on the early diagnosis and effective management of pemphigus vulgaris, a rare autoimmune disease characterized by painful blisters and erosions affecting the skin and mucous membranes. Growing investments in immunology research and the development of advanced treatment options are further supporting market growth worldwide. Pemphigus vulgaris is considered the most common form of pemphigus and often requires long-term treatment and disease management.

Market Drivers

One of the primary factors driving the pemphigus vulgaris market is the growing awareness and diagnosis of autoimmune blistering diseases. Improved diagnostic techniques and increased awareness among healthcare professionals are helping identify cases at earlier stages, leading to timely treatment interventions.

Another significant growth driver is the increasing adoption of biologic therapies and immunosuppressive treatments. The introduction of targeted therapies has improved disease management outcomes and reduced reliance on conventional corticosteroid-based treatments in many cases.

The rising investment in rare disease research and orphan drug development is also contributing to market growth. Pharmaceutical companies are actively developing innovative therapies to address unmet clinical needs and improve patient quality of life.

Furthermore, advancements in precision medicine, monoclonal antibodies, and immunotherapy research are creating new growth opportunities for market participants.

Market Challenges

Despite favorable growth prospects, the pemphigus vulgaris market faces several challenges. One major restraint is the relatively low prevalence of the disease, which limits the overall patient population and commercial opportunities for treatment providers.

Another challenge is the high cost associated with biologic therapies and long-term disease management, which may restrict patient access in certain regions.

Additionally, delayed diagnosis and the complexity of disease management may affect treatment outcomes and increase healthcare burdens.

Market Segmentation

By Treatment Type:

• Corticosteroids
• Immunosuppressants
• Biologics
• Intravenous Immunoglobulin (IVIG)
• Others

The biologics segment holds a significant market share due to increasing adoption of targeted therapies that offer improved efficacy and reduced side effects.

By Route of Administration:

• Oral
• Injectable
• Intravenous

The injectable segment dominates the market owing to the growing use of biologic therapies and monoclonal antibody treatments.

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hospital pharmacies account for a substantial market share due to the specialized nature of pemphigus vulgaris treatment and disease management.

By End User:

• Hospitals
• Specialty Clinics
• Dermatology Centers
• Research Institutes

The hospitals segment represents a significant market share due to the need for multidisciplinary care and advanced treatment protocols.

Regional Insights

North America

North America dominates the global pemphigus vulgaris market due to advanced healthcare infrastructure, strong research activities, favorable reimbursement policies, and increasing adoption of biologic therapies. The United States remains the largest contributor to regional growth.

Europe

Europe represents a significant market supported by growing investments in rare disease research, increasing awareness of autoimmune disorders, and strong healthcare systems.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, increasing awareness regarding autoimmune diseases, expanding access to advanced treatments, and rising healthcare expenditures across China, India, Japan, and South Korea.

Latin America, Middle East, and Africa

These regions are emerging markets driven by improving diagnosis rates, expanding healthcare access, and growing awareness regarding rare autoimmune disorders.

Key Players Analysis

The pemphigus vulgaris market is highly competitive, with leading pharmaceutical and biotechnology companies focusing on biologic therapies, immunology research, and strategic collaborations to strengthen their market positions. Key companies operating in the market include:

• Roche Holding AG
• Sanofi S.A.
• Amgen Inc.
• Novartis AG
• AbbVie Inc.
• Pfizer Inc.
• Johnson & Johnson
• Bristol Myers Squibb
• UCB S.A.
• Argenx SE

These companies continue investing in innovative biologic therapies, monoclonal antibodies, and advanced immunology solutions to address the growing demand for effective pemphigus vulgaris treatments.

For Detailed Insights, Visit:
https://straitsresearch.com/report/pemphigus-vulgaris-market

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)